Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Select Inclusion Criteria: * Patient has unresectable Stage III NSCLC that has not progressed following concurrent platinum-based chemotherapy and radiation therapy and is eligible to receive durvalumab according to the US FDA approved package insert. * Patient is able and willing to use the mobile application and connected devices. * Patient is able to complete QoL assessments. Select Exclusion Criteria: * Patient is currently oxygen dependent. * Patient has comorbidities that will prevent consistent and reliable measurement assessments with multiparametric mobile technology including severe chronic obstructive pulmonary disorder (COPD), severe asthma, congestive heart failure \[CHF\], interstitial lung disease \[ILD\], and others. * Patients on other immunotherapy or systemic immunosuppressants. * Patients with active or prior autoimmune disease or history of immunodeficiency. * Currently pregnant women.